TejalAmarPatelMD

Oncology • Houston, TX

Breast Cancer, Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology

Breast Medical Oncologist Assistant Professor, Weill Cornell Medical College

Join to view full profile

Dr. Patel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Patel's full profile

Already have an account?

Office
1515 Holcombe Drive
Houston, TX 77030
Phone+1 713-566-5100

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2006 - 2009
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2003 - 2006
University of Texas Medical Branch School of MedicineClass of 2003

Certifications & Licensure

FL State Medical License 2004 - 2026
TX State Medical License 2008 - 2026
American Board of Internal Medicine Medical Oncology

Clinical Trials

The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer Start of enrollment: 2010 Jun 01
Unknown status
Phase 1
Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT) Start of enrollment: 2011 Sep 01
Completed
Phase 2
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01
Completed
NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 2
PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer Start of enrollment: 2012 Jul 01
Withdrawn
Phase 2
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel Start of enrollment: 2014 Feb 01
Completed
Phase 2
T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer Start of enrollment: 2013 Oct 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Real-World Immune-Related Adverse Events in Patients With Early Triple-Negative Breast Cancer Who Received Pembrolizumab.
Athira Jayan, Jasmine S Sukumar, Benjamin Fangman, Tejal Patel, Akshara Singareeka Raghavendra
JCO Oncology Practice. 2024-10-10
2 citations
A Deep Learning Decision Support Tool to Improve Risk Stratification and Reduce Unnecessary Biopsies in BI-RADS 4 Mammograms.
Chika F Ezeana, Tiancheng He, Tejal A Patel, Virginia Kaklamani, Maryam Elmi
Radiology. Artificial Intelligence. 2023-11-01
10 citations
A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer.
Kai Sun, Yitian Xu, Licheng Zhang, Polly Niravath, Jorge Darcourt
Clinical Cancer Research. 2022-10-14

Press Mentions

Small Study Suggests App Helps Women Exercise More, Lose Weight After Breast Cancer DiagnosisDecember 4th, 2018
Olive Oil Component Investigated for Breast Cancer PreventionJanuary 22nd, 2014

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Other Languages

Gujarati